Medigene, clinical stage immuno-oncology company focusing on the development of T cell immunotherapies for cancer, entered into a service agreement with Cytovant Sciences to support process development activities for the manufacturing of dendritic cell (DC) vaccines.
The deal builds on Medigene’s license and cooperation agreements with Roivant/Cytovant which cover three TCR projects and Medigene’s DC vaccine program targeting WT-1 and PRAME in acute myeloid leukemia (AML) for Greater China, South Korea, and Japan.
In January, Medigene published positive final results from the open-label Phase I/II trial with its DC vaccine in 20 AML patients and Roivant/Cytovant is continuing the development of this program as CVT-DC-01 in its licensed territories in Asia.
